Rapid Sepsis Testing Can Save Lives and Curb Costs

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Rapid Sepsis Testing Can Save Lives and Curb Costs

Latest News

Two Symptoms Linked to Antibiotic Delays in Presumed Sepsis

Exercise and Cancer Survival; COVID Vaccine and Immune Checkpoint Inhibitors

BPAP Intervention Flops in Asthma Study

To Face Scrutiny at ESC: Statins for the Elderly, New Heart Attack Therapies

Radio Silence on Mitch McConnell's Health Persists

Cefepime Tied to Higher Mortality Odds vs Other Beta-Lactams

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

News All Time

Discordant Tissue Findings in Suspected HLH

What Extreme Athletes Teach Us About Sleep Deprivation

Omalizumab May Ease Inflammation in Chronic Urticaria

Pediatric Lung Transplantation Enters a New Era

CVS Health's Aetna to Streamline Cancer Treatment Approvals

Diphtheria Debate Exposes Health Misinformation

Azithromycin Use Cuts Cesarean Infections

Methotrexate for IBD: How Do GIs Use It?

AI Digital Twins Get Better and Better: Cancer in Crosshairs

S1P Modulators: 5 Agents, One Safety Playbook

As-Needed Allergic Rhinitis Meds Comparable to Daily Use

Host-Directed Therapies and Phages in Lung Care

Mild Brain Injury Frequently Missed in the ED

D10 Matches D50 for Hypoglycemia, Shows Lower Rebound Risk

A Rare Hearing Implant Bypasses Damaged Nerves

Two-Midnight Rule: Key Strategies for Observation Patients

Recommended News For You

Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation

The top three drugs for multiple myeloma treatment upfront are four.

Un nou sistem de endoscopică imaging are capacitatea de a detecta mai mulți fluorescent tracers.

Immunotherapy after surgery is good for patients with advanced cancer

Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.

Asymptomatic or Minimally Symptomatic Myelofibrosis

EBCC: European Breast Cancer Conference

Recommended Articles For You

HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia

Revolutionizing Cancer Care: The Impact of Darzalex Faspro

Engineered Immune Cells for Brain Tumors: Mechanisms, Clinical Impact, and Future Directions

RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.